Boston Scientific Corporation vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Boston Scientific Corporation trades at $42.97 (market cap $66.37B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.54. The key difference: VanEck JP Morgan EM Local Currency Bond ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | EMLC | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Fixed Income |
52-Week High | $108.14 | $26.59 |
52-Week Low | $42.63 | $24.83 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
EMLC trades at $25.39, down 0.63% over 24 hours, with technical indicators signaling a bearish trend. The ETF maintains a consistent dividend payout, with recent distributions of $0.14 per share. News highlights focus on emerging market debt opportunities amid shifting global volatility, though short interest has risen significantly, indicating investor caution.
Outlook remains mixed; EMLC offers attractive yield above Treasuries but faces currency risk and capital erosion concerns. Key risks include Fed policy shifts and emerging market volatility. Institutional demand is growing, yet high short interest suggests skepticism about sustainability.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →